Parkinson's disease - Pipeline Insight, 2025

This “Parkinson’s disease - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Parkinson’s disease: Understanding

Parkinson’s disease: Overview

Parkinson's disease (PD) is a progressive neurodegenerative disorder mainly impacting dopamine-producing neurons in the substantia nigra, a critical region in the brain responsible for movement control. As these neurons degenerate, dopamine levels decrease, leading to symptoms like tremors, stiffness, and difficulty with balance and coordination. PD affects both motor and non-motor functions, gradually impairing the patient's quality of life. The exact cause of neuronal loss in PD remains largely unknown, though genetics and environmental factors may play a role. Parkinson's disease presents with four main symptoms: tremors (shaking) in the hands, arms, legs, jaw, or head; stiffness in the limbs and trunk; slowness of movement; and impaired balance and coordination, which can lead to falls. Additional symptoms may include depression, emotional changes, trouble swallowing, speaking difficulties, urinary or digestive issues, skin problems, and sleep disruptions. The onset of Parkinson’s symptoms is subtle and gradual, often mistaken for normal aging. People may initially experience mild tremors, difficulty rising from a chair, soft speech, or small, cramped handwriting.

There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s - particularly in its early stages - is difficult, but a skilled practitioner can come to a reasoned conclusion that it is PD. People with Parkinson's-like symptoms that result from other causes are sometimes said to have parkinsonism. While these disorders initially may be misdiagnosed as Parkinson's, certain medical tests, as well as response to drug treatment, may help to distinguish them from Parkinson's.

Although Parkinson's disease cannot be cured, treatments such as medications, surgical procedures, and various therapies can effectively relieve some symptoms. The primary treatment is levodopa (L-dopa), a drug that nerve cells in the brain use to produce dopamine, thus helping to replenish its dwindling levels and reduce symptoms like tremors and muscle stiffness. Levodopa is often paired with carbidopa, another medication that enhances levodopa’s effectiveness by preventing its early breakdown in the bloodstream, ensuring more reaches the brain. Carbidopa also helps to reduce some of levodopa's side effects, including nausea, vomiting, low blood pressure, and restlessness, which allows for a lower dosage of levodopa to be used. For individuals with more advanced symptoms, options like deep brain stimulation (DBS) and physical, occupational, and speech therapy are also available, often improving mobility, speech, and overall quality of life.

"Parkinson’s disease- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease.

Parkinson’s disease Emerging Drugs Chapters

This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Parkinson’s disease Emerging Drugs

Tavapadon: AbbVie

Tavapadon is a selective dopamine D1/D5 partial agonist that Cerevel is developing for the treatment of early- and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile. D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile. Tavapadon was designed to improve motor symptoms in Parkinson’s disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations.

• KM-819: FAScinate Therapeutics

KM-819 is a small molecule developed as an inhibitor for FAF1, a proapoptotic protein, targeting various degenerative diseases. It has shown superior neuroprotective efficacy in Parkinson’s disease models, and clinical trials are underway with the aim of proving its efficacy in human patients. KM-819 may be also explored as a potential treatment for other degenerative diseases, including multiple system atrophy (MSA). It shows an excellent safety profile in both long-term animal toxicology studies and the human clinical trial Phase I study that has been completed. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson’s disease.

UCB0022: UCB Biopharma

UCB0022 is an investigational oral small molecule developed by UCB Biopharma for the treatment of Parkinson's disease. It functions as a positive allosteric modulator of the dopamine receptor type 1 (D1R), enhancing its signaling in the presence of endogenous dopamine without activating the receptor on its own. This mechanism aims to improve motor function while minimizing the need for higher doses of dopamine, which can lead to side effects such as dyskinesia associated with excessive D2 receptor signaling134. UCB0022 has shown promising results in preclinical studies and is currently undergoing Phase II clinical trials to evaluate its efficacy and safety as an adjunct therapy to levodopa in patients with advanced Parkinson's disease.

• Lu AF28996: Lundbeck A/S

Lu AF28996 is a small molecule drug developed by Lundbeck, designed as an orally administered agonist for both dopamine D1 and D2 receptors. Its primary therapeutic application is in the treatment of Parkinson's disease, where it aims to alleviate motor symptoms by mimicking the action of dopamine, a critical neurotransmitter that is deficient in patients with this condition. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson's disease.

LBT-3627: Longevity Biotech

LBT-3627 is an experimental neuroprotective drug developed by Longevity Biotech, aimed at treating neurodegenerative disorders such as Parkinson's disease. Its mechanism of action involves selectively targeting the VPAC2 receptor, a member of the vasoactive intestinal peptide (VIP) receptor family. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson's disease.

Parkinson’s disease: Therapeutic Assessment

This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Parkinson’s disease

• There are approx. 80+ key companies which are developing the therapies for Parkinson’s disease. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. Phase II include, AbbVie.

Phases

The report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Parkinson’s disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Parkinson’s disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease drugs.

Parkinson’s disease Report Insights

• Parkinson’s disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Parkinson’s disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Parkinson’s disease drugs?
• How many Parkinson’s disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Parkinson’s disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Pharma Two B Ltd.
• UCB Biopharma
• Ventyx Biosciences
• FAScinate Therapeutics
• Longevity Biotech
• Lundbeck A/S
• iCamuno Biotherapeutics
• Neuropore Therapies

Key Products

• Tavapadon
• P2B001
• UCB0022
• VTX3232
• KM-819
• LBT-3627
• Lu AF-28996
• ICA07
• NPT1220-478

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.